person · Reporting owner

Drappa Jorn

Disclosed activity across 4 companies

Tapewire entity: 26267
SEC CIK: 0001789317

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ALUMIS INC.ALMS · Entity 4816	Chief Medical Officer	August 03, 2026	August 05, 2026
Ventyx Biosciences, Inc.VTYX · Entity 62843	Chief Medical Officer	February 04, 2022	February 04, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ALUMIS INC.

Report date August 03, 2026 · Filed August 05, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	56,892	Reported balance After 2026-08-03 transaction · row 1 1 source row Row 1 · 2026-08-03 · Sale · Disposed 2,447 · Balance 56,892 F1: The sale reported on this Form 4 was effected pursuant to the Issuer's policy requiring sell-to-cover to satisfy tax obligations of the Reporting Person incurred with the vesting and settlement of restricted stock units granted on July 29, 2025, and does not represent a discretionary sale by the Reporting Person. F2: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $25.54 to $26.42 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Filing footnotes · ownership attribution and instrument terms

F1: The sale reported on this Form 4 was effected pursuant to the Issuer's policy requiring sell-to-cover to satisfy tax obligations of the Reporting Person incurred with the vesting and settlement of restricted stock units granted on July 29, 2025, and does not represent a discretionary sale by the Reporting Person.

F2: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $25.54 to $26.42 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Ventyx Biosciences, Inc.

Report date February 04, 2022 · Filed February 04, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.21 · Expires 2032-02-04	Direct	145,000	Reported balance After 2022-02-04 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-02-04 · Grant · Acquired 145,000 · Balance 145,000 F1: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one forty-eighth (1/48th) of the total shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean February 3, 2022.

Filing footnotes · ownership attribution and instrument terms

F1: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one forty-eighth (1/48th) of the total shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean February 3, 2022.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ALPINE IMMUNE SCIENCES, INC.

Report date May 20, 2024 · Filed May 20, 2024

Section 16 reporting ended · disclosed 2024-05-20. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.71 · Expires 2032-07-17	Direct	Reported balance After 2024-05-20 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2024-05-20 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F3: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F4: (Continued from Footnote 3) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F5: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent. F6: (Continued from Footnote 5) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding. F2: 1/36th of the shares subject to the option shall become vested and exercisable on 08/18/2022 and 1/36th of the shares subject to the option shall vest monthly thereafter.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.43 · Expires 2033-01-02	Direct	Reported balance After 2024-05-20 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-05-20 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F3: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F4: (Continued from Footnote 3) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F5: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent. F6: (Continued from Footnote 5) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding. F7: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.00 · Expires 2034-01-01	Direct	Reported balance After 2024-05-20 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-05-20 · Disposition to issuer · Disposed 17,500 · Balance 0 F1: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F3: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F4: (Continued from Footnote 3) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F5: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent. F6: (Continued from Footnote 5) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding. F8: 1/12th of the shares subject to the option become vested and exercisable on February 2, 2024 and 1/12 of the shares subject to the option shall vest monthly thereafter.

Filing footnotes · ownership attribution and instrument terms

F1: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant.

F2: 1/36th of the shares subject to the option shall become vested and exercisable on 08/18/2022 and 1/36th of the shares subject to the option shall vest monthly thereafter.

F3: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option.

F4: (Continued from Footnote 3) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof.

F5: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent.

F6: (Continued from Footnote 5) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding.

F7: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable.

F8: 1/12th of the shares subject to the option become vested and exercisable on February 2, 2024 and 1/12 of the shares subject to the option shall vest monthly thereafter.

Viela Bio, Inc.

Report date March 13, 2021 · Filed March 15, 2021

Section 16 reporting ended · disclosed 2021-03-15. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2021-03-13 transaction · row 1 1 source row Row 1 · 2021-03-13 · Disposition to issuer · Disposed 202,661 · Balance 0 F1: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated January 31, 2021 (the "Merger Agreement"), by and among the Issuer, Horizon Therapeutics USA, Inc., Teiripic Merger Sub, Inc. ("Purchaser"), and for certain purposes, Horizon Therapeutics plc ("Ultimate Parent"), including the completion on March 13, 2021 of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $53.00 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Purchaser on on March 15, 2021. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.10 · Expires 2030-03-01	Direct	Reported balance After 2021-03-15 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-03-15 · Disposition to issuer · Disposed 71,842 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option. F3: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options that was not otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was converted into into an option to purchase Ultimate Parent ordinary shares, subject to substantially the same vesting terms and conditions as were applicable to such option immediately prior to the Effective Time, with respect to the number of Ultimate Parent ordinary shares determined by multiplying (i) the number of shares subject to such option immediately prior to the Effective Time and (ii) an exchange ratio equal to 0.6047.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.84 · Expires 2029-08-25	Direct	Reported balance After 2021-03-15 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-03-15 · Disposition to issuer · Disposed 64,000 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option. F3: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options that was not otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was converted into into an option to purchase Ultimate Parent ordinary shares, subject to substantially the same vesting terms and conditions as were applicable to such option immediately prior to the Effective Time, with respect to the number of Ultimate Parent ordinary shares determined by multiplying (i) the number of shares subject to such option immediately prior to the Effective Time and (ii) an exchange ratio equal to 0.6047.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.84 · Expires 2028-05-10	Direct	Reported balance After 2021-03-15 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-03-15 · Disposition to issuer · Disposed 165,000 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option. F3: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options that was not otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was converted into into an option to purchase Ultimate Parent ordinary shares, subject to substantially the same vesting terms and conditions as were applicable to such option immediately prior to the Effective Time, with respect to the number of Ultimate Parent ordinary shares determined by multiplying (i) the number of shares subject to such option immediately prior to the Effective Time and (ii) an exchange ratio equal to 0.6047.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated January 31, 2021 (the "Merger Agreement"), by and among the Issuer, Horizon Therapeutics USA, Inc., Teiripic Merger Sub, Inc. ("Purchaser"), and for certain purposes, Horizon Therapeutics plc ("Ultimate Parent"), including the completion on March 13, 2021 of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $53.00 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Purchaser on on March 15, 2021. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price.

F2: Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option.

F3: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options that was not otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was converted into into an option to purchase Ultimate Parent ordinary shares, subject to substantially the same vesting terms and conditions as were applicable to such option immediately prior to the Effective Time, with respect to the number of Ultimate Parent ordinary shares determined by multiplying (i) the number of shares subject to such option immediately prior to the Effective Time and (ii) an exchange ratio equal to 0.6047.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 03, 2026 Filed Aug 5, 2026 22:36 UTC	ALUMIS INC. ALMS · Entity 4816	SaleCommon Stock	2,447	$26.37	$64,527.39	Disclosure SEC source: 0001789317-26-000007 · form4-08052026_100847.xml · nonDerivative · entry 1 Drappa Jorn · CIK 0001789317 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,892 F1 · shares: The sale reported on this Form 4 was effected pursuant to the Issuer's policy requiring sell-to-cover to satisfy tax obligations of the Reporting Person incurred with the vesting and settlement of restricted stock units granted on July 29, 2025, and does not represent a discretionary sale by the Reporting Person. F2 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $25.54 to $26.42 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
May 22, 2026 Filed May 27, 2026 23:06 UTC	ALUMIS INC. ALMS · Entity 4816	Exercise / conversionStock Option (Right to Buy) · Derivative	15,535	$0.00 Strike: $5.06	$0.00	Disclosure SEC source: 0001789317-26-000005 · form4-05272026_110540.xml · derivative · entry 4 Drappa Jorn · CIK 0001789317 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,465 Underlying: Common Stock · 15,535 shares Expires 2035-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares underlying this option vested on February 18, 2026, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document
May 22, 2026 Filed May 27, 2026 23:06 UTC	ALUMIS INC. ALMS · Entity 4816	Exercise / conversionStock Option (Right to Buy) · Derivative	11,317	$0.00 Strike: $8.84	$0.00	Disclosure SEC source: 0001789317-26-000005 · form4-05272026_110540.xml · derivative · entry 3 Drappa Jorn · CIK 0001789317 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 159,805 Underlying: Common Stock · 11,317 shares Expires 2032-08-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares underlying this option vested on August 22, 2023, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document
May 22, 2026 Filed May 27, 2026 23:06 UTC	ALUMIS INC. ALMS · Entity 4816	Exercise / conversionCommon Stock	15,535	$5.06	$78,607.10	Disclosure SEC source: 0001789317-26-000005 · form4-05272026_110540.xml · nonDerivative · entry 2 Drappa Jorn · CIK 0001789317 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,339 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 22, 2026 Filed May 27, 2026 23:06 UTC	ALUMIS INC. ALMS · Entity 4816	Exercise / conversionCommon Stock	11,317	$8.84	$100,042.28	Disclosure SEC source: 0001789317-26-000005 · form4-05272026_110540.xml · nonDerivative · entry 1 Drappa Jorn · CIK 0001789317 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,804 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,037 shares acquired on November 20, 2025 and 3,000 shares acquired on May 20, 2026 under the Issuer's 2024 Employee Stock Purchase Plan. Read SEC document
January 26, 2026 Filed Jan 29, 2026 00:17 UTC	ALUMIS INC. ALMS · Entity 4816	GrantStock Option (Right to Buy) · Derivative	221,450	$0.00 Strike: $26.31	$0.00	Disclosure SEC source: 0001789317-26-000003 · form4-01292026_120144.xml · derivative · entry 1 Drappa Jorn · CIK 0001789317 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 221,450 Underlying: Common Stock · 221,450 shares Expires 2036-01-25 F1 · derivative.exercise_date: 25% of the shares underlying this option vest on January 26, 2027, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan) to the Issuer on each such vesting date. Read SEC document
July 29, 2025 Filed Aug 1, 2025 01:05 UTC	ALUMIS INC. ALMS · Entity 4816	GrantStock Option (Right to Buy) · Derivative	101,850	$0.00 Strike: $3.95	$0.00	Disclosure SEC source: 0001415889-25-020803 · form4-07312025_090706.xml · derivative · entry 2 Drappa Jorn · CIK 0001789317 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,850 Underlying: Common Stock · 101,850 shares Expires 2035-07-28 F3 · derivative.exercise_date: 25% of the shares underlying this option vest on July 29, 2026, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan) to the Issuer on each such vesting date. Read SEC document
July 29, 2025 Filed Aug 1, 2025 01:05 UTC	ALUMIS INC. ALMS · Entity 4816	GrantCommon Stock	25,450	$0.00	$0.00	Disclosure SEC source: 0001415889-25-020803 · form4-07312025_090706.xml · nonDerivative · entry 1 Drappa Jorn · CIK 0001789317 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,450 F1 · shares: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant. 25% of the shares underlying this RSU vest on August 1, 2026, and the remaining shares vest in equal quarterly installments thereafter over the following 12 quarters, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan) to the Issuer on each such vesting date. F2 · balance_after: Includes 3,000 shares acquired on May 20, 2025 under the Issuer's 2024 Employee Stock Purchase Plan. Read SEC document
February 18, 2025 Filed Feb 20, 2025 23:30 UTC	ALUMIS INC. ALMS · Entity 4816	GrantStock Option (Right to Buy) · Derivative	180,000	$0.00 Strike: $5.06	$0.00	Disclosure SEC source: 0001415889-25-004938 · form4-02202025_060206.xml · derivative · entry 1 Drappa Jorn · CIK 0001789317 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2035-02-17 F1 · derivative.exercise_date: 25% of the shares underlying this option vest on February 18, 2026, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document
July 01, 2024 Filed Jul 1, 2024 20:37 UTC	ALUMIS INC. ALMS · Entity 4816	GrantStock Option (Right to Buy) · Derivative	64,171	$0.00 Strike: $13.33	$0.00	Disclosure SEC source: 0001415889-24-018592 · form4-07012024_080720.xml · derivative · entry 17 Drappa Jorn · CIK 0001789317 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,171 Underlying: Common Stock · 64,171 shares Expires 2034-06-05 F2 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock. F9 · derivative.exercise_date: 25% of the shares underlying this option vest on June 6, 2025, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document
July 01, 2024 Filed Jul 1, 2024 20:37 UTC	ALUMIS INC. ALMS · Entity 4816	Disposition to issuerStock Option (Right to Buy) · Derivative	64,171	$0.00 Strike: $13.33	$0.00	Disclosure SEC source: 0001415889-24-018592 · form4-07012024_080720.xml · derivative · entry 16 Drappa Jorn · CIK 0001789317 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 64,171 shares Expires 2034-06-05 F2 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock. F9 · derivative.exercise_date: 25% of the shares underlying this option vest on June 6, 2025, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document
July 01, 2024 Filed Jul 1, 2024 20:37 UTC	ALUMIS INC. ALMS · Entity 4816	GrantCommon Stock (Right to Buy) · Derivative	70,802	$0.00 Strike: $10.20	$0.00	Disclosure SEC source: 0001415889-24-018592 · form4-07012024_080720.xml · derivative · entry 15 Drappa Jorn · CIK 0001789317 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,802 Underlying: Common Stock · 70,802 shares Expires 2034-05-05 F2 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock. F8 · derivative.exercise_date: The option vests in three equal installments, subject to the Issuer's satisfaction of certain performance criteria on each of May 6, 2028, May 6, 2029 and May 6, 2030, and subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document
July 01, 2024 Filed Jul 1, 2024 20:37 UTC	ALUMIS INC. ALMS · Entity 4816	Disposition to issuerStock Option (Right to Buy) · Derivative	70,802	$0.00 Strike: $10.20	$0.00	Disclosure SEC source: 0001415889-24-018592 · form4-07012024_080720.xml · derivative · entry 14 Drappa Jorn · CIK 0001789317 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 70,802 shares Expires 2034-05-05 F2 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock. F8 · derivative.exercise_date: The option vests in three equal installments, subject to the Issuer's satisfaction of certain performance criteria on each of May 6, 2028, May 6, 2029 and May 6, 2030, and subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document
July 01, 2024 Filed Jul 1, 2024 20:37 UTC	ALUMIS INC. ALMS · Entity 4816	GrantStock Option (Right to Buy) · Derivative	54,545	$0.00 Strike: $8.84	$0.00	Disclosure SEC source: 0001415889-24-018592 · form4-07012024_080720.xml · derivative · entry 13 Drappa Jorn · CIK 0001789317 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,545 Underlying: Common Stock · 54,545 shares Expires 2034-03-28 F2 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock. F7 · derivative.exercise_date: 25% of the shares underlying this option vest on March 29, 2025, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document
July 01, 2024 Filed Jul 1, 2024 20:37 UTC	ALUMIS INC. ALMS · Entity 4816	Disposition to issuerStock Option (Right to Buy) · Derivative	54,545	$0.00 Strike: $8.84	$0.00	Disclosure SEC source: 0001415889-24-018592 · form4-07012024_080720.xml · derivative · entry 12 Drappa Jorn · CIK 0001789317 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 54,545 shares Expires 2034-03-28 F2 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock. F7 · derivative.exercise_date: 25% of the shares underlying this option vest on March 29, 2025, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document
July 01, 2024 Filed Jul 1, 2024 20:37 UTC	ALUMIS INC. ALMS · Entity 4816	GrantStock Option (Right to Buy) · Derivative	18,652	$0.00 Strike: $8.84	$0.00	Disclosure SEC source: 0001415889-24-018592 · form4-07012024_080720.xml · derivative · entry 11 Drappa Jorn · CIK 0001789317 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,652 Underlying: Common Stock · 18,652 shares Expires 2033-10-08 F2 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock. F6 · derivative.exercise_date: 25% of the shares underlying this option vest on October 9, 2024, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document
July 01, 2024 Filed Jul 1, 2024 20:37 UTC	ALUMIS INC. ALMS · Entity 4816	Disposition to issuerStock Option (Right to Buy) · Derivative	18,652	$0.00 Strike: $8.84	$0.00	Disclosure SEC source: 0001415889-24-018592 · form4-07012024_080720.xml · derivative · entry 10 Drappa Jorn · CIK 0001789317 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 18,652 shares Expires 2033-10-08 F2 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock. F6 · derivative.exercise_date: 25% of the shares underlying this option vest on October 9, 2024, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document
July 01, 2024 Filed Jul 1, 2024 20:37 UTC	ALUMIS INC. ALMS · Entity 4816	GrantStock Option (Right to Buy) · Derivative	12,834	$0.00 Strike: $8.84	$0.00	Disclosure SEC source: 0001415889-24-018592 · form4-07012024_080720.xml · derivative · entry 9 Drappa Jorn · CIK 0001789317 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,834 Underlying: Common Stock · 12,834 shares Expires 2033-06-22 F2 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock. F5 · derivative.exercise_date: 25% of the shares underlying this option vested on May 22, 2024, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document
July 01, 2024 Filed Jul 1, 2024 20:37 UTC	ALUMIS INC. ALMS · Entity 4816	Disposition to issuerStock Option (Right to Buy) · Derivative	12,834	$0.00 Strike: $8.84	$0.00	Disclosure SEC source: 0001415889-24-018592 · form4-07012024_080720.xml · derivative · entry 8 Drappa Jorn · CIK 0001789317 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 12,834 shares Expires 2033-06-22 F2 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock. F5 · derivative.exercise_date: 25% of the shares underlying this option vested on May 22, 2024, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document
July 01, 2024 Filed Jul 1, 2024 20:37 UTC	ALUMIS INC. ALMS · Entity 4816	GrantStock Option (Right to Buy) · Derivative	171,122	$0.00 Strike: $8.84	$0.00	Disclosure SEC source: 0001415889-24-018592 · form4-07012024_080720.xml · derivative · entry 7 Drappa Jorn · CIK 0001789317 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 171,122 Underlying: Common Stock · 171,122 shares Expires 2032-08-29 F2 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock. F4 · derivative.exercise_date: 25% of the shares underlying this option vested on August 22, 2023, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document
July 01, 2024 Filed Jul 1, 2024 20:37 UTC	ALUMIS INC. ALMS · Entity 4816	Disposition to issuerStock Option (Right to Buy) · Derivative	171,122	$0.00 Strike: $8.84	$0.00	Disclosure SEC source: 0001415889-24-018592 · form4-07012024_080720.xml · derivative · entry 6 Drappa Jorn · CIK 0001789317 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 171,122 shares Expires 2032-08-29 F2 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock. F4 · derivative.exercise_date: 25% of the shares underlying this option vested on August 22, 2023, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document
July 01, 2024 Filed Jul 1, 2024 20:37 UTC	ALUMIS INC. ALMS · Entity 4816	GrantStock Option (Right to Buy) · Derivative	85,561	$0.00 Strike: $8.84	$0.00	Disclosure SEC source: 0001415889-24-018592 · form4-07012024_080720.xml · derivative · entry 5 Drappa Jorn · CIK 0001789317 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,561 Underlying: Common Stock · 85,561 shares Expires 2032-08-29 F2 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock. F3 · derivative.exercise_date: 33% of the shares underlying this option vested on August 22, 2024, and the remaining shares vest in equal monthly installments thereafter over the following 48 months, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document
July 01, 2024 Filed Jul 1, 2024 20:37 UTC	ALUMIS INC. ALMS · Entity 4816	Disposition to issuerStock Option (Right to Buy) · Derivative	85,561	$0.00 Strike: $8.84	$0.00	Disclosure SEC source: 0001415889-24-018592 · form4-07012024_080720.xml · derivative · entry 4 Drappa Jorn · CIK 0001789317 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 85,561 shares Expires 2032-08-29 F2 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock. F3 · derivative.exercise_date: 33% of the shares underlying this option vested on August 22, 2024, and the remaining shares vest in equal monthly installments thereafter over the following 48 months, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document
July 01, 2024 Filed Jul 1, 2024 20:37 UTC	ALUMIS INC. ALMS · Entity 4816	GrantStock Option (Right to Buy) · Derivative	5,347	$0.00 Strike: $16.00	$0.00	Disclosure SEC source: 0001415889-24-018592 · form4-07012024_080720.xml · derivative · entry 3 Drappa Jorn · CIK 0001789317 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,347 Underlying: Common Stock · 5,347 shares Expires 2034-06-26 F2 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock. F1 · derivative.exercise_date: 25% of the shares underlying this option vest on June 21, 2025, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document
July 01, 2024 Filed Jul 1, 2024 20:37 UTC	ALUMIS INC. ALMS · Entity 4816	Disposition to issuerStock Option (Right to Buy) · Derivative	5,347	$0.00 Strike: $16.00	$0.00	Disclosure SEC source: 0001415889-24-018592 · form4-07012024_080720.xml · derivative · entry 2 Drappa Jorn · CIK 0001789317 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 5,347 shares Expires 2034-06-26 F2 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock. F1 · derivative.exercise_date: 25% of the shares underlying this option vest on June 21, 2025, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document
June 27, 2024 Filed Jul 1, 2024 20:37 UTC	ALUMIS INC. ALMS · Entity 4816	GrantStock Option (Right to Buy) · Derivative	5,347	$0.00 Strike: $16.00	$0.00	Disclosure SEC source: 0001415889-24-018592 · form4-07012024_080720.xml · derivative · entry 1 Drappa Jorn · CIK 0001789317 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,347 Underlying: Class A Common Stock · 5,347 shares Expires 2034-06-26 F1 · derivative.exercise_date: 25% of the shares underlying this option vest on June 21, 2025, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document
May 20, 2024 Filed May 20, 2024 20:12 UTC	ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802	Disposition to issuerStock Option (Right to buy) · Derivative	17,500	Not disclosed Strike: $19.00	Not disclosed	Disclosure SEC source: 0001626199-24-000099 · wk-form4_1716250361.xml · derivative · entry 3 Drappa Jorn · CIK 0001789317 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,500 shares Expires 2034-01-01 F1 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F3 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F4 · price: (Continued from Footnote 3) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F5 · price: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent. F6 · price: (Continued from Footnote 5) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding. F8 · derivative.exercise_date: 1/12th of the shares subject to the option become vested and exercisable on February 2, 2024 and 1/12 of the shares subject to the option shall vest monthly thereafter. Read SEC document
May 20, 2024 Filed May 20, 2024 20:12 UTC	ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802	Disposition to issuerStock Option (Right to buy) · Derivative	10,000	Not disclosed Strike: $7.43	Not disclosed	Disclosure SEC source: 0001626199-24-000099 · wk-form4_1716250361.xml · derivative · entry 2 Drappa Jorn · CIK 0001789317 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2033-01-02 F1 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F3 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F4 · price: (Continued from Footnote 3) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F5 · price: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent. F6 · price: (Continued from Footnote 5) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding. F7 · derivative.exercise_date: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. Read SEC document
May 20, 2024 Filed May 20, 2024 20:12 UTC	ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802	Disposition to issuerStock Option (Right to buy) · Derivative	20,000	Not disclosed Strike: $8.71	Not disclosed	Disclosure SEC source: 0001626199-24-000099 · wk-form4_1716250361.xml · derivative · entry 1 Drappa Jorn · CIK 0001789317 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2032-07-17 F1 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F3 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F4 · price: (Continued from Footnote 3) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F5 · price: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent. F6 · price: (Continued from Footnote 5) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding. F2 · derivative.exercise_date: 1/36th of the shares subject to the option shall become vested and exercisable on 08/18/2022 and 1/36th of the shares subject to the option shall vest monthly thereafter. Read SEC document
January 02, 2024 Filed Jan 4, 2024 19:05 UTC	ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802	GrantStock Option (Right to buy) · Derivative	17,500	$0.00 Strike: $19.00	$0.00	Disclosure SEC source: 0001626199-24-000012 · wk-form4_1704413131.xml · derivative · entry 1 Drappa Jorn · CIK 0001789317 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2034-01-01 F1 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F2 · derivative.exercise_date: 1/12th of the shares subject to the option become vested and exercisable on February 2, 2024 and 1/12 of the shares subject to the option shall vest monthly thereafter. Read SEC document
January 03, 2023 Filed Jan 5, 2023 18:59 UTC	ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802	GrantStock Option (Right to buy) · Derivative	10,000	$0.00 Strike: $7.43	$0.00	Disclosure SEC source: 0001626199-23-000019 · wf-form4_167296313903992.xml · derivative · entry 1 Drappa Jorn · CIK 0001789317 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-01-02 F1 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F2 · derivative.exercise_date: 1/12th of the shares subject to the option become vested and exercisable on February 3, 2023 and 1/12 of the shares subject to the option shall vest monthly thereafter. Read SEC document
July 18, 2022 Filed Jul 19, 2022 16:42 UTC	ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802	GrantStock Option (Right to buy) · Derivative	20,000	$0.00 Strike: $8.71	$0.00	Disclosure SEC source: 0001789317-22-000004 · wf-form4_165826334018650.xml · derivative · entry 1 Drappa Jorn · CIK 0001789317 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-07-17 F1 · derivative.exercise_date: 1/36th of the shares subject to the option shall become vested and exercisable on 08/18/2022 and 1/36th of the shares subject to the option shall vest monthly thereafter. Read SEC document
February 04, 2022 Filed Feb 4, 2022 23:38 UTC	Ventyx Biosciences, Inc. VTYX · Entity 62843	GrantStock Option (right to buy) · Derivative	145,000	$0.00 Strike: $12.21	$0.00	Disclosure SEC source: 0000899243-22-004895 · doc4.xml · derivative · entry 1 Drappa Jorn · CIK 0001789317 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,000 Underlying: Common Stock · 145,000 shares Expires 2032-02-04 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one forty-eighth (1/48th) of the total shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean February 3, 2022. Read SEC document
March 15, 2021 Filed Mar 15, 2021 09:16 UTC	Viela Bio, Inc. VIE · Entity 141253	Disposition to issuerStock Option (right to buy) · Derivative	165,000	Not disclosed Strike: $2.84	Not disclosed	Disclosure SEC source: 0000899243-21-011499 · doc4.xml · derivative · entry 4 Drappa Jorn · CIK 0001789317 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 165,000 shares Expires 2028-05-10 F2 · kind: Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option. F3 · kind: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options that was not otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was converted into into an option to purchase Ultimate Parent ordinary shares, subject to substantially the same vesting terms and conditions as were applicable to such option immediately prior to the Effective Time, with respect to the number of Ultimate Parent ordinary shares determined by multiplying (i) the number of shares subject to such option immediately prior to the Effective Time and (ii) an exchange ratio equal to 0.6047. F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options that was not otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was converted into into an option to purchase Ultimate Parent ordinary shares, subject to substantially the same vesting terms and conditions as were applicable to such option immediately prior to the Effective Time, with respect to the number of Ultimate Parent ordinary shares determined by multiplying (i) the number of shares subject to such option immediately prior to the Effective Time and (ii) an exchange ratio equal to 0.6047. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options that was not otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was converted into into an option to purchase Ultimate Parent ordinary shares, subject to substantially the same vesting terms and conditions as were applicable to such option immediately prior to the Effective Time, with respect to the number of Ultimate Parent ordinary shares determined by multiplying (i) the number of shares subject to such option immediately prior to the Effective Time and (ii) an exchange ratio equal to 0.6047. Read SEC document
March 15, 2021 Filed Mar 15, 2021 09:16 UTC	Viela Bio, Inc. VIE · Entity 141253	Disposition to issuerStock Option (right to buy) · Derivative	64,000	Not disclosed Strike: $15.84	Not disclosed	Disclosure SEC source: 0000899243-21-011499 · doc4.xml · derivative · entry 3 Drappa Jorn · CIK 0001789317 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 64,000 shares Expires 2029-08-25 F2 · kind: Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option. F3 · kind: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options that was not otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was converted into into an option to purchase Ultimate Parent ordinary shares, subject to substantially the same vesting terms and conditions as were applicable to such option immediately prior to the Effective Time, with respect to the number of Ultimate Parent ordinary shares determined by multiplying (i) the number of shares subject to such option immediately prior to the Effective Time and (ii) an exchange ratio equal to 0.6047. F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options that was not otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was converted into into an option to purchase Ultimate Parent ordinary shares, subject to substantially the same vesting terms and conditions as were applicable to such option immediately prior to the Effective Time, with respect to the number of Ultimate Parent ordinary shares determined by multiplying (i) the number of shares subject to such option immediately prior to the Effective Time and (ii) an exchange ratio equal to 0.6047. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options that was not otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was converted into into an option to purchase Ultimate Parent ordinary shares, subject to substantially the same vesting terms and conditions as were applicable to such option immediately prior to the Effective Time, with respect to the number of Ultimate Parent ordinary shares determined by multiplying (i) the number of shares subject to such option immediately prior to the Effective Time and (ii) an exchange ratio equal to 0.6047. Read SEC document
March 15, 2021 Filed Mar 15, 2021 09:16 UTC	Viela Bio, Inc. VIE · Entity 141253	Disposition to issuerStock Option (right to buy) · Derivative	71,842	Not disclosed Strike: $41.10	Not disclosed	Disclosure SEC source: 0000899243-21-011499 · doc4.xml · derivative · entry 2 Drappa Jorn · CIK 0001789317 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 71,842 shares Expires 2030-03-01 F2 · kind: Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option. F3 · kind: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options that was not otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was converted into into an option to purchase Ultimate Parent ordinary shares, subject to substantially the same vesting terms and conditions as were applicable to such option immediately prior to the Effective Time, with respect to the number of Ultimate Parent ordinary shares determined by multiplying (i) the number of shares subject to such option immediately prior to the Effective Time and (ii) an exchange ratio equal to 0.6047. F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options that was not otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was converted into into an option to purchase Ultimate Parent ordinary shares, subject to substantially the same vesting terms and conditions as were applicable to such option immediately prior to the Effective Time, with respect to the number of Ultimate Parent ordinary shares determined by multiplying (i) the number of shares subject to such option immediately prior to the Effective Time and (ii) an exchange ratio equal to 0.6047. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options that was not otherwise eligible to vest in accordance with its terms on or before June 1, 2021, subject solely to the continued services of the holder of such option with the Issuer through such date, was converted into into an option to purchase Ultimate Parent ordinary shares, subject to substantially the same vesting terms and conditions as were applicable to such option immediately prior to the Effective Time, with respect to the number of Ultimate Parent ordinary shares determined by multiplying (i) the number of shares subject to such option immediately prior to the Effective Time and (ii) an exchange ratio equal to 0.6047. Read SEC document
March 13, 2021 Filed Mar 15, 2021 09:16 UTC	Viela Bio, Inc. VIE · Entity 141253	Disposition to issuerCommon Stock	202,661	$53.00	$10,741,033.00	Disclosure SEC source: 0000899243-21-011499 · doc4.xml · nonDerivative · entry 1 Drappa Jorn · CIK 0001789317 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated January 31, 2021 (the "Merger Agreement"), by and among the Issuer, Horizon Therapeutics USA, Inc., Teiripic Merger Sub, Inc. ("Purchaser"), and for certain purposes, Horizon Therapeutics plc ("Ultimate Parent"), including the completion on March 13, 2021 of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $53.00 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Purchaser on on March 15, 2021. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price. Read SEC document
March 02, 2020 Filed Mar 4, 2020 16:44 UTC	Viela Bio, Inc. VIE · Entity 141253	GrantStock Option (Right to Buy) · Derivative	71,842	$0.00 Strike: $41.10	$0.00	Disclosure SEC source: 0001209191-20-016146 · doc4.xml · derivative · entry 2 Drappa Jorn · CIK 0001789317 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,842 Underlying: Common Stock · 71,842 shares Expires 2030-03-01 F1 · derivative.exercise_date: This option grant vests as to 25% of the shares on March 2, 2021 with the remainder vesting in equal installments every three months thereafter and ending on March 2, 2024. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.